Molecular modeling, admet prediction, synthesis and the cytotoxic activity from the novel n-(4-tert-butylphenylcarbamoyl) benzamide against hela

Efforts to develop urea derivatives as anticancer agents thrive due to their proven anticancer activities. N-(4-tert-butylphenylcarbamoyl)benzamide was synthesized by Schotten Baumann reaction, rendering 59%. To determine the purity, a thin-layer chromatography method in 3 different mobile phases was adopted, indicating a stain with distinguishing Rf. Structure identification indicating the compound was N-(4-tert-butylphenylcarbamoyl)benzamide. To predict cytotoxic activity, molecular docking with Autodocks Program was used by supplementing CHK1 enzyme (code PDB: 2YWP) against HeLa cells. The prediction score was confirmed by Molecular Docking Simulation (MDS). N-(4-tert-butylphenylcarbamoyl)benzamide (-4.41) has a smaller docking score compared to that of hydroxyurea (-2.69), suggesting higher cytotoxicity. MDS score highlighting this compound with (-13.1223±4.6818) total energy, smaller than the one in reference compound, (-0.0446±0.3621). This new compound indicated properties with favorable anticancer activity in the ADMET prediction, due to the toxicity displayed against the organ. On the cytotoxic activity test against HeLa cells, the IC₅₀ of-(4-tert-butylphenylcarbamoyl)benzamide is 3.78 nM, smaller than that of hydroxyurea, IC₅₀ 9.91 nM. The data suggest that the synthesized N-(4-tert-butylphenylcarbamoyl) benzamidedisplays higher cytotoxic activity compared to hydroxyurea. This synthesized compound allows further study in drug development, serving as a new anticancer agent.